Literature DB >> 18377927

Structural basis for substrate promiscuity of dCK.

Elisabetta Sabini1, Saugata Hazra, Stephan Ort, Manfred Konrad, Arnon Lavie.   

Abstract

Deoxycytidine kinase (dCK) is an essential nucleoside kinase critical for the production of nucleotide precursors for DNA synthesis. This enzyme catalyzes the initial conversion of the nucleosides deoxyadenosine (dA), deoxyguanosine (dG), and deoxycytidine (dC) into their monophosphate forms, with subsequent phosphorylation to the triphosphate forms performed by additional enzymes. Several nucleoside analog prodrugs are dependent on dCK for their pharmacological activation, and even nucleosides of the non-physiological L-chirality are phosphorylated by dCK. In addition to accepting dC and purine nucleosides (and their analogs) as phosphoryl acceptors, dCK can utilize either ATP or UTP as phosphoryl donors. To unravel the structural basis for substrate promiscuity of dCK at both the nucleoside acceptor and nucleotide donor sites, we solved the crystal structures of the enzyme as ternary complexes with the two enantiomeric forms of dA (D-dA, or L-dA), with either UDP or ADP bound to the donor site. The complexes with UDP revealed an open state of dCK in which the nucleoside, either D-dA or L-dA, is surprisingly bound in a manner not consistent with catalysis. In contrast, the complexes with ADP, with either D-dA or L-dA, adopted a closed and catalytically competent conformation. The differential states adopted by dCK in response to the nature of the nucleotide were also detected by tryptophan fluorescence experiments. Thus, we are in the unique position to observe differential effects at the acceptor site due to the nature of the nucleotide at the donor site, allowing us to rationalize the different kinetic properties observed with UTP to those with ATP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18377927      PMCID: PMC2426910          DOI: 10.1016/j.jmb.2008.02.061

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  16 in total

1.  Refinement of macromolecular structures by the maximum-likelihood method.

Authors:  G N Murshudov; A A Vagin; E J Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-05-01

2.  Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate.

Authors:  T L Hughes; T M Hahn; K K Reynolds; D S Shewach
Journal:  Biochemistry       Date:  1997-06-17       Impact factor: 3.162

3.  SHELXL: high-resolution refinement.

Authors:  G M Sheldrick; T R Schneider
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

4.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities.

Authors:  R M Esnouf
Journal:  J Mol Graph Model       Date:  1997-04       Impact factor: 2.518

5.  The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation.

Authors:  Yan Zhang; John A Secrist; Steven E Ealick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-01-18

6.  Fluorescence energy transfer studies of human deoxycytidine kinase: role of cysteine 185 in the conformational changes that occur upon substrate binding.

Authors:  Rajam S Mani; Elena V Usova; Carol E Cass; Staffan Eriksson
Journal:  Biochemistry       Date:  2006-03-21       Impact factor: 3.162

7.  Nucleotide specificity of human deoxycytidine kinase.

Authors:  D S Shewach; K K Reynolds; L Hertel
Journal:  Mol Pharmacol       Date:  1992-09       Impact factor: 4.436

8.  Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2007-05-27       Impact factor: 7.446

9.  Structure of human dCK suggests strategies to improve anticancer and antiviral therapy.

Authors:  Elisabetta Sabini; Stephan Ort; Christian Monnerjahn; Manfred Konrad; Arnon Lavie
Journal:  Nat Struct Biol       Date:  2003-07

10.  Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Stephen K Burley; Arnon Lavie
Journal:  Nucleic Acids Res       Date:  2006-12-07       Impact factor: 16.971

View more
  20 in total

1.  Inhibition of dengue virus RNA synthesis by an adenosine nucleoside.

Authors:  Yen-Liang Chen; Zheng Yin; Jeyaraj Duraiswamy; Wouter Schul; Chin Chin Lim; Boping Liu; Hao Ying Xu; Min Qing; Andy Yip; Gang Wang; Wai Ling Chan; Hui Pen Tan; Melissa Lo; Sarah Liung; Ravinder Reddy Kondreddi; Ranga Rao; Helen Gu; Handan He; Thomas H Keller; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues .

Authors:  Saugata Hazra; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2010-08-10       Impact factor: 3.162

3.  Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors:  Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

4.  Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release.

Authors:  Saugata Hazra; Andrzej Szewczak; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2011-03-16       Impact factor: 3.162

5.  Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules.

Authors:  Julian Nomme; Jennifer M Murphy; Ying Su; Natasha D Sansone; Amanda L Armijo; Steven T Olson; Caius Radu; Arnon Lavie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-12-24

6.  The sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): implications for the development of dCK-activated acyclic guanine analogues.

Authors:  Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

7.  Novel PET probes specific for deoxycytidine kinase.

Authors:  Chengyi J Shu; Dean O Campbell; Jason T Lee; Andrew Q Tran; Jordan C Wengrod; Owen N Witte; Michael E Phelps; Nagichettiar Satyamurthy; Johannes Czernin; Caius G Radu
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

8.  Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

9.  [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Authors:  Woosuk Kim; Thuc M Le; Liu Wei; Soumya Poddar; Jimmy Bazzy; Xuemeng Wang; Nhu T Uong; Evan R Abt; Joseph R Capri; Wayne R Austin; Juno S Van Valkenburgh; Dalton Steele; Raymond M Gipson; Roger Slavik; Anthony E Cabebe; Thotsophon Taechariyakul; Shahriar S Yaghoubi; Jason T Lee; Saman Sadeghi; Arnon Lavie; Kym F Faull; Owen N Witte; Timothy R Donahue; Michael E Phelps; Harvey R Herschman; Ken Herrmann; Johannes Czernin; Caius G Radu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

10.  Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.

Authors:  Dominique B Figueroa; Erin P Madeen; Joseph Tillotson; Paul Richardson; Leslie Cottle; Marybeth McCauley; Raphael J Landovitz; Adriana Andrade; Craig W Hendrix; Kenneth H Mayer; Timothy Wilkin; Roy M Gulick; Namandjé N Bumpus
Journal:  AIDS Res Hum Retroviruses       Date:  2018-03-20       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.